Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology
Product News Feb 11, 2013
Bruker has announced a collaboration between Bruker and Nextval for high-throughput screening of drugs and their metabolites using Bruker's ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval's MassInsight technology.
The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam II™ laser with its Perpetual Ion Source for unrivalled productivity, ensuring optimum performance for low concentration high-throughput screening.
The versatility of Bruker's Compass™ software allows integration with Nextval's screening technology to maximize sample density and reduce sample analysis costs.
Nextval's MassInsight screening technology is based on novel surface chemistries coupled with unique microarray acoustic deposition methods (EDC Biosystems & BioSero LLC) that address critical needs in several industries including the pharmaceutical, testing and industrial markets.
Dr. Matthew Greving, CSO of Nextval, stated: "The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity."
Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialize their MassInsight technology for high-throughput enzyme assays.
Dr. Paul Speir, Senior Vice President of Bruker Daltonics stated: "We are excited by the combination of Nextval's MassInsight technology with the information rich, high throughput capabilities provided by the ultrafleXtreme. Moreover, we are pleased to support Nextval in their efforts to develop this important technology for the rapid and economical screening of drug candidates."